Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1996 Aug;55(8):525–534. doi: 10.1136/ard.55.8.525

Changes in cartilage proteoglycan aggrecan after intra-articular injection of interleukin-1 in rabbits: studies of synovial fluid and articular cartilage.

C Lundberg 1, I Asberg 1, M Ionescu 1, A Reiner 1, G Smedegård 1, A R Poole 1
PMCID: PMC1010232  PMID: 8774180

Abstract

OBJECTIVE: To determine how acute but transient inflammation affects the cartilage proteoglycan aggrecan and the value of analyses of synovial fluid to study this. METHODS: For 96 hours after a single intra-articular injection of rabbit knees with human interleukin-1 alpha (IL-1 alpha) or vehicle, articular cartilage and synovial fluid were examined using a putative indicator of aggrecan synthesis (aggrecan chondroitin sulphate epitope 846), immunoreactive keratan sulphate, and total glycosaminoglycan (GAG) content. Aggrecan extractability (with 0.5 M NaCl) followed by 4 M guanidine hydrochloride extraction permitted analyses of cartilage damage, total content and aggrecan heterogeneity. Aggrecan epitopes as well as GAG were assayed in synovial fluid. Changes were related to total joint leucocyte content in synovial fluid. RESULTS: At 10 ng, IL-1 alpha produced a transient increase in synovial fluid leucocytes at six hours and 24 hours. This accompanied a reduction in content and increased extractability of GAG, which was greatest in the tibial medial compartment of the knee. Further studies of this compartment showed no change in keratan sulphate epitope content, but a transient increase in extractability in 0.5 M NaCl. Epitope 846 content and extractability were unchanged. Total contents and extractability for GAG were inversely correlated in both controls and joints injected with IL-1 alpha. These changes were accompanied by transient increases in GAG, keratan sulphate epitope, and 846 content in synovial fluid. CONCLUSION: According to the aggrecan component measured, damage to the matrix of articular cartilage was sometimes reflected by a transient increased extractability and a net loss of aggrecan. There was always an increased release of GAG, and keratan sulphate, and 846 epitopes into synovial fluid. These studies show that changes in aggrecan epitopes and GAG in synovial fluid reflect changes in cartilage metabolism induced by acute transient inflammation.

Full text

PDF
525

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arner E. C., Pratta M. A. Independent effects of interleukin-1 on proteoglycan breakdown, proteoglycan synthesis, and prostaglandin E2 release from cartilage in organ culture. Arthritis Rheum. 1989 Mar;32(3):288–297. doi: 10.1002/anr.1780320310. [DOI] [PubMed] [Google Scholar]
  2. Bayliss M. T., Ali S. Y. Age-related changes in the composition and structure of human articular-cartilage proteoglycans. Biochem J. 1978 Dec 15;176(3):683–693. doi: 10.1042/bj1760683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brandt K. D. Enhanced extractability of articular cartilage protoglycans in osteoarthrosis. Biochem J. 1974 Nov;143(2):475–478. doi: 10.1042/bj1430475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chandrasekhar S., Harvey A. K., Hrubey P. S. Intra-articular administration of interleukin-1 causes prolonged suppression of cartilage proteoglycan synthesis in rats. Matrix. 1992 Feb;12(1):1–10. doi: 10.1016/s0934-8832(11)80099-5. [DOI] [PubMed] [Google Scholar]
  5. Dean D. D., Martel-Pelletier J., Pelletier J. P., Howell D. S., Woessner J. F., Jr Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest. 1989 Aug;84(2):678–685. doi: 10.1172/JCI114215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Doege K. J., Sasaki M., Kimura T., Yamada Y. Complete coding sequence and deduced primary structure of the human cartilage large aggregating proteoglycan, aggrecan. Human-specific repeats, and additional alternatively spliced forms. J Biol Chem. 1991 Jan 15;266(2):894–902. [PubMed] [Google Scholar]
  7. Doege K., Sasaki M., Horigan E., Hassell J. R., Yamada Y. Complete primary structure of the rat cartilage proteoglycan core protein deduced from cDNA clones. J Biol Chem. 1987 Dec 25;262(36):17757–17767. [PubMed] [Google Scholar]
  8. Farndale R. W., Buttle D. J., Barrett A. J. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta. 1986 Sep 4;883(2):173–177. doi: 10.1016/0304-4165(86)90306-5. [DOI] [PubMed] [Google Scholar]
  9. Franzén A., Inerot S., Hejderup S. O., Heinegård D. Variations in the composition of bovine hip articular cartilage with distance from the articular surface. Biochem J. 1981 Jun 1;195(3):535–543. doi: 10.1042/bj1950535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Glant T. T., Mikecz K., Roughley P. J., Buzás E., Poole A. R. Age-related changes in protein-related epitopes of human articular-cartilage proteoglycans. Biochem J. 1986 May 15;236(1):71–75. doi: 10.1042/bj2360071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Heinegård D., Oldberg A. Structure and biology of cartilage and bone matrix noncollagenous macromolecules. FASEB J. 1989 Jul;3(9):2042–2051. doi: 10.1096/fasebj.3.9.2663581. [DOI] [PubMed] [Google Scholar]
  12. Loulakis P., Shrikhande A., Davis G., Maniglia C. A. N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures. Putative site(s) of enzymic cleavage. Biochem J. 1992 Jun 1;284(Pt 2):589–593. doi: 10.1042/bj2840589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. McDevitt C. A., Muir H. Biochemical changes in the cartilage of the knee in experimental and natural osteoarthritis in the dog. J Bone Joint Surg Br. 1976 Feb;58(1):94–101. doi: 10.1302/0301-620X.58B1.131804. [DOI] [PubMed] [Google Scholar]
  14. McDevitt C., Gilbertson E., Muir H. An experimental model of osteoarthritis; early morphological and biochemical changes. J Bone Joint Surg Br. 1977 Feb;59(1):24–35. doi: 10.1302/0301-620X.59B1.576611. [DOI] [PubMed] [Google Scholar]
  15. Månsson B., Carey D., Alini M., Ionescu M., Rosenberg L. C., Poole A. R., Heinegård D., Saxne T. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest. 1995 Mar;95(3):1071–1077. doi: 10.1172/JCI117753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Pettipher E. R., Henderson B., Hardingham T., Ratcliffe A. Cartilage proteoglycan depletion in acute and chronic antigen-induced arthritis. Arthritis Rheum. 1989 May;32(5):601–607. doi: 10.1002/anr.1780320514. [DOI] [PubMed] [Google Scholar]
  17. Pettipher E. R., Higgs G. A., Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci U S A. 1986 Nov;83(22):8749–8753. doi: 10.1073/pnas.83.22.8749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Poole A. R., Dieppe P. Biological markers in rheumatoid arthritis. Semin Arthritis Rheum. 1994 Jun;23(6 Suppl 2):17–31. doi: 10.1016/0049-0172(94)90081-7. [DOI] [PubMed] [Google Scholar]
  19. Poole A. R. Immunochemical markers of joint inflammation, skeletal damage and repair: where are we now? Ann Rheum Dis. 1994 Jan;53(1):3–5. doi: 10.1136/ard.53.1.3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Poole A. R., Ionescu M., Swan A., Dieppe P. A. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis. J Clin Invest. 1994 Jul;94(1):25–33. doi: 10.1172/JCI117314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Poole A. R., Reiner A., Roughley P. J., Champion B. Rabbit antibodies to degraded and intact glycosaminoglycans which are naturally occurring and present in arthritic rabbits. J Biol Chem. 1985 May 25;260(10):6020–6025. [PubMed] [Google Scholar]
  22. Ratcliffe A., Doherty M., Maini R. N., Hardingham T. E. Increased concentrations of proteoglycan components in the synovial fluids of patients with acute but not chronic joint disease. Ann Rheum Dis. 1988 Oct;47(10):826–832. doi: 10.1136/ard.47.10.826. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rizkalla G., Reiner A., Bogoch E., Poole A. R. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest. 1992 Dec;90(6):2268–2277. doi: 10.1172/JCI116113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sandy J. D., Flannery C. R., Neame P. J., Lohmander L. S. The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. J Clin Invest. 1992 May;89(5):1512–1516. doi: 10.1172/JCI115742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sandy J. D., Neame P. J., Boynton R. E., Flannery C. R. Catabolism of aggrecan in cartilage explants. Identification of a major cleavage site within the interglobular domain. J Biol Chem. 1991 May 15;266(14):8683–8685. [PubMed] [Google Scholar]
  26. Saxne T., Heinegård D. Synovial fluid analysis of two groups of proteoglycan epitopes distinguishes early and late cartilage lesions. Arthritis Rheum. 1992 Apr;35(4):385–390. doi: 10.1002/art.1780350404. [DOI] [PubMed] [Google Scholar]
  27. Schünke M., Tillmann B., Brück M., Müller-Ruchholtz W. Morphologic characteristics of developing osteoarthrotic lesions in the knee cartilage of STR/IN mice. Arthritis Rheum. 1988 Jul;31(7):898–905. doi: 10.1002/art.1780310711. [DOI] [PubMed] [Google Scholar]
  28. Thompson R. C., Jr, Oegema T. R., Jr Metabolic activity of articular cartilage in osteoarthritis. An in vitro study. J Bone Joint Surg Am. 1979 Apr;61(3):407–416. [PubMed] [Google Scholar]
  29. Tyler J. A. Articular cartilage cultured with catabolin (pig interleukin 1) synthesizes a decreased number of normal proteoglycan molecules. Biochem J. 1985 May 1;227(3):869–878. doi: 10.1042/bj2270869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Webber C., Glant T. T., Roughley P. J., Poole A. R. The identification and characterization of two populations of aggregating proteoglycans of high buoyant density isolated from post-natal human articular cartilages of different ages. Biochem J. 1987 Dec 15;248(3):735–740. doi: 10.1042/bj2480735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Witter J., Roughley P. J., Webber C., Roberts N., Keystone E., Poole A. R. The immunologic detection and characterization of cartilage proteoglycan degradation products in synovial fluids of patients with arthritis. Arthritis Rheum. 1987 May;30(5):519–529. doi: 10.1002/art.1780300506. [DOI] [PubMed] [Google Scholar]
  32. van Beuningen H. M., Arntz O. J., van den Berg W. B. In vivo effects of interleukin-1 on articular cartilage. Prolongation of proteoglycan metabolic disturbances in old mice. Arthritis Rheum. 1991 May;34(5):606–615. doi: 10.1002/art.1780340513. [DOI] [PubMed] [Google Scholar]
  33. van de Loo A. A., van den Berg W. B. Effects of murine recombinant interleukin 1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis. 1990 Apr;49(4):238–245. doi: 10.1136/ard.49.4.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. van de Loo F. A., Arntz O. J., Otterness I. G., van den Berg W. B. Protection against cartilage proteoglycan synthesis inhibition by antiinterleukin 1 antibodies in experimental arthritis. J Rheumatol. 1992 Mar;19(3):348–356. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES